Northeast Investment Management Trims Stake in Abbott Laboratories $ABT

Northeast Investment Management cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 85,260 shares of the healthcare product maker’s stock after selling 5,405 shares during the period. Northeast Investment Management’s holdings in Abbott Laboratories were worth $8,754,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the 4th quarter worth approximately $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $93.12 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.54. The company has a market capitalization of $162.19 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 1.56 and a beta of 0.63. The firm’s 50-day moving average is $89.23 and its 200 day moving average is $105.46.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a global licensing agreement with ALZpath to develop a blood-based Alzheimer’s diagnostic test for its Alinity ci-series systems, opening a potential new growth avenue in high-demand neurology testing. Article: ALZpath signs licensing deal with Abbott to develop Alzheimer’s blood test
• Positive Sentiment: Recent commentary highlighted Abbott’s expanding diabetes franchise, especially FreeStyle Libre, and said the stock looks attractive after sector rotation pushed it lower, with one note calling it a “Buy” on growth and catalyst potential. Article: Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
• Positive Sentiment: Multiple articles pointed to strong investor sentiment, including bullish hedge fund positioning and estimates of roughly 31% upside, suggesting Wall Street still views Abbott as a quality large-cap healthcare name. Article: How Does Wall Street View Abbott Laboratories (ABT)’s Outlook?
• Positive Sentiment: Coverage also emphasized Abbott’s dividend record, four-segment business model, and recession-resistant cash flow, which can support the stock during periods of market rotation away from defensive names. Article: 3 Dividend Aristocrat Stocks with 20%+ Upside — June 25, 2026
• Neutral Sentiment: Abbott said it will host its second-quarter earnings conference call on July 16, keeping attention on upcoming results and guidance but not changing fundamentals yet. Article: Abbott hosts conference call for second-quarter earnings
• Neutral Sentiment: Other recent pieces cited emerging-market momentum in established pharmaceuticals and new sensor distribution in Europe, adding to the bullish narrative without being major near-term stock drivers. Article: How Are Emerging Markets Supporting Abbott’s EPD Momentum?

Analyst Ratings Changes

A number of research analysts recently weighed in on ABT shares. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a report on Wednesday, April 22nd. BTIG Research reiterated a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a research report on Monday, April 27th. TD Cowen lowered their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Barclays lowered their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $118.30.

Insiders Place Their Bets

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.